Stock Ratings / Health Care / GDTC / forecast

TPST (44) LSTA (32) LTRN (42) BLRX (60) ⌘ Pro Terminal →

CytoMed Therapeutics Limited (GDTC) 12-Month Stock Forecast & Price Target Cone

$0.90 -3.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

CytoMed Therapeutics Limited (GDTC) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $10.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-2.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GDTC)Realized 20D OHLCV Swing Band: ±12.5%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your GDTC Position Size: $10,000

Shares at $0.90: 11111.1 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $0.69

$7,667

$-2,333 (-23.3%)

12M Consensus BaseTarget $0.88

$9,778

$-222 (-2.2%)

12M Bull Case BreakoutTarget $3.26

$36,222

+$26,222 (+262.2%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 6

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$1	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$3	69%	B
JP MorganUS Large-Cap Research	SELL	$1	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GDTC)

✓Walkthrough of GDTC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GDTC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -10.00%📐 HORIZONTAL RANGE

2026-10-30O $0.89H $0.92L $0.83C $0.90VOL 11.4K

RES: $1.08SUP: $0.69SMA50: $0.90SMA200: $0.98

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GDTC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GDTC Butterfly Map → + Track GDTC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GDTC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GDTC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GDTC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GDTC)

Health Care Rank #297 of 1016 ⚔️ TPST vs GDTC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GDTC vs. TPST, LSTA, LTRN, BLRX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, CytoMed Therapeutics Limited (GDTC) ranks #297 by composite RQD confidence (54/100, grade D+) and #893 by equity capitalization ($10.7M). Within this direct 5-issuer industry benchmark cohort, GDTC leads on earnings valuation at N/A trailing P/E, while TPST leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BLRX currently holds the highest overall quantitative score in the immediate peer group at 60/100 (C-) compared with GDTC at 54/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GDTC ACTIVE CytoMed Therapeutics Limited	D+	54/100	—	—	—	-3.68%	$10.7M	Benchmark Subject
TPST Tempest Therapeutics Inc.	D	44/100	—	—	-35.0%	-1.24%	$10.7M	/tpst-vs-gdtc →
LSTA Lisata Therapeutics Inc.	E	32/100	—	—	-35.0%	-4.72%	$10.9M	/lsta-vs-gdtc →
LTRN Lantern Pharma Inc.	D-	42/100	—	—	-35.0%	-5.52%	$10.9M	/ltrn-vs-gdtc →
BLRX BioLineRx Ltd.	C-	60/100	—	—	—	+1.00%	$10.1M	/blrx-vs-gdtc →

2. GDTC Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

CytoMed Therapeutics Limited (GDTC) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $10.7M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. GDTC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GDTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, CytoMed Therapeutics Limited (NASDAQ: GDTC) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $0.90 (-3.68% 1D, market cap $10.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, GDTC ranks #297 in composite RQD confidence.

How does GDTC compare to TPST and LSTA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GDTC carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, TPST (Tempest Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $10.7M) and LSTA (Lisata Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $10.9M). Among the 5-stock peer group, GDTC leads on earnings multiple (N/A) while TPST leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GDTC?

For CytoMed Therapeutics Limited (GDTC), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #297 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GDTC trading relative to its 50-day, 200-day, and 52-week technical levels?

GDTC last traded at $0.90 (-3.68% on volume of 11,962 shares), positioning the stock 0.00% above its 50-day simple moving average ($0.90) and -8.16% below its 200-day simple moving average ($0.98). Across its 52-week range of $0.68 to $3.10, GDTC sits at the 9.1% percentile with a 14-day RSI of 51.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.01).

GDTC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is GDTC's 12-month stock price target?

CytoMed Therapeutics Limited (GDTC) carries a 12-month consensus base price target of $0.88 (-2.2% from $0.90), with a bull-case target of $3.26 and a bear-case floor of $0.69.